Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies

Evaluation of Drug Interaction of Glimepiride with Phosphodiesterase Inhibitors Type V in Diabetic Nephropathy

(2014) A. Tripathi et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin

(2014) Annfrid Sivertsen et al.   BMC STRUCTURAL BIOLOGY

Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies

(2012) A.S. Tripathi et al.   SAUDI PHARMACEUTICAL JOURNAL

FTSite: high accuracy detection of ligand binding sites on unbound protein structures

(2011) Chi-Ho Ngan et al.   BIOINFORMATICS

Structural and Mechanistic Insights into the Interaction of Cytochrome P4503A4 with Bromoergocryptine, a Type I Ligand

(2011) Irina F. Sevrioukova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

(2010) Yoshihiro Kuno et al.   BRITISH JOURNAL OF PHARMACOLOGY

Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques

(2009) Ryan Brenke et al.   BIOINFORMATICS

Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice

(2009) Xiaoyan Xiao et al.   JOURNAL OF AUTOIMMUNITY

Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting

(2008) W Todd Cade   PHYSICAL THERAPY

Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil

(2003) R. Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY